Crestline Management, LP Travere Therapeutics, Inc. Transaction History
Crestline Management, LP
- $1.88 Billion
- Q3 2024
A detailed history of Crestline Management, LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Crestline Management, LP holds 120,725 shares of TVTX stock, worth $2.1 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
120,725
Previous 103,353
16.81%
Holding current value
$2.1 Million
Previous $849,000
98.82%
% of portfolio
0.09%
Previous 0.07%
Shares
8 transactions
Others Institutions Holding TVTX
# of Institutions
192Shares Held
84.5MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$133 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$133 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$120 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$81.5 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$75.5 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.12B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...